Publications and

News Header Image

Our Publications

December, 2023
DPP3 is associated with poor outcomes in the ICU population. van Lier D, et al.
October, 2023
Circulating dipeptidyl peptidase 3 – New hope for a specific treatment to improve prognosis in cardiogenic shock? Pöss J, et al.
October, 2023
Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes. Wenzl FA, et al.
August, 2023
DPP3 appreciated as promising biomarker for shock diagnosis and shock therapy. ICU Management & Practice.
May, 2023
This is a most up-to-date review on the pathophysiological role of DPP3. Malovan G, et al.
April, 2023
DPP3 as an early marker of severity in cardiogenic shock. Innelli P, et al.
February, 2023
DPP3 featured as a biomarker and therapeutic target in critically ill patients. Hernández RM, et al.
January, 2023
DPP3 is associated with poor outcomes in critically ill COVID-19 patients. van Lier D, et al.
December, 2022
DPP3 as a novel indicator of myocardial injury after acute myocardial infarction. Ozden O, et al.
October, 2022
DPP3: from biomarker to therapeutic target in cardiovascular diseases. Ye P, et al.
June, 2022
DPP3 as a potential marker in end-stage heart failure. Pavo N, et al.
February, 2022
DPP3 is associated with mortality and organ failure in shock. Deniau B, et al.
January, 2022
The emerging role of dipeptidyl peptidase 3 in pathophysiology. Malovan G, et al.
January, 2022
Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure? Pavo N, et al.
January, 2022
Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis. Voiosu AM, et al.
December, 2021
High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort. Deniau B, et al.
August, 2021
Circulating dipeptidyl peptidase 3 on intensive care unit admission is a predictor of organ dysfunction and mortality. Frigyesi A, et al.
June, 2021
Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome. Thorgeirsdóttir B, et al.
June, 2021
Circulating biomarkers to assess cardiovascular function in critically ill. van Lier D, et al.
June, 2021
DPP3 featured as a biomarker to assess cardiovascular function in critically ill patients. van Lier D, et al.
March, 2021
Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage. Neumaier F, et al.
February, 2021
Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Blet A, et al.
December, 2020
Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3. van Lier D, et al.
November, 2020
In-hospital mortality and organ failure after open and endovascular thoraco-abdominal aortic surgery can be predicted by increased levels of circulating dipeptidyl peptidase 3. Gombert A, et al.
August, 2020
DPP3 featured as a biomarker and biotarget in cardiogenic shock. Iborra-Egea O, et al.

Our Announcements

March 20, 2024

4TEEN4 Pharmaceuticals was awarded a 128,000 €  grant from German Bundesministerium für Bildung und Forschung to as part of "KMU-innovativ - Verbundprojekt ComplianceControl: Management von IT Compliance durch Object-Centric Process Mining (OCPM)" project, being conducted in collaboration with DHC Business Solutions GmbH & Co. KG, Saarbrücken, RHEACELL GmbH & Co. KG, Heidelberg & Universität Mannheim.

March 19, 2024

Today, 4TEEN4 Pharmaceuticals announces dosing of the first subject in Phase 1 study, a single -center, randomized, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of Procizumab. Phase I study is being conducted at Radboud University, Nijmagen NL, under the supervision of Prof. Peter Pickkers.
The commencement of Phase I clinical trial represents the culmination of extensive preclinical research and rigorous safety evaluations. As we move into this clinical phase or development, we are optimistic about the potential of our investigational treatment to address unmet medical needs  in Cardiogenic Shock and make a meaningful difference in the lives of patients.
4TEEN4 Management.

February 29, 2024

4TEEN4 Pharmaceuticals was awarded a 150,000 € DATIpilot grant from German Bundesministerium für Bildung und Forschung for a  SURVIVE "Schnelle und zuverlässige Diagnose des kardiogenen und septischen Schocks mittels DPP3-Bluttest in der Akut- und Notfallmedizin" project.

February 21, 2024

4TEEN4 Pharmaceuticals and Boditec Med are pleased to announce signing of an out licensing agreement for the use of 4TEEN4 owned DPP3 biomarker on Boditech’s proprietary Afias and ichroma™ platforms. Boditec will develop DPP3 for the prediction and monitoring of cardiogenic shock in patients with acute coronary syndrome and acute heart failure. In addition Boditech became a shareholder of 4TEEN4 Pharmaceuticals by acquiring 3.03% stake in the company.

Our Achievements

A recent report on the tremendous predictive value of DPP3 in patients with cardiogenic shock within the ACCOST-HH trial was chosen as one of the 3 best Abstracts out of hundreds submitted for the upcoming 2023 congress of the German Association for Intensive and Emergency Care (DIVI). The scientific congress, one of the largest of its kind in Europe, will take place from November 29th to December 01st in Hamburg / Germany.
Within the study, median circulating DPP3 concentration at baseline was 43.2 ng/mL [21.2-74] and 52% of the patients had elevated DPP3 concentrations over the pre-defined cutoff of 40 ng/mL. The number of days without the need for cardiovascular organ support (pharmacological and/ or mechanical organ support), which had been the primary endpoint of the ACCOST-HH trial, was 7 times longer in the low versus high DPP3 group (21 vs 3 days; p=0.005). Moreover, elevated DPP3 concentrations were associated with the need for mechanical organ support -not just cardiac, but also respiratory (p=0.04; mechanical ventilation) and renal support (p<0.001; renal replacement therapy). The prolonged and increased need for organ support directly translated into a much higher (74% vs 31%) mortality rate in the high DPP3 group.

The PIs commented their findings as follows:

"Our results hold strong promise for the upcoming clinical trials on the evaluation of the specific DPP3-antibody Procizumab as new breakthrough therapy in cardiogenic shock. We are very happy to hear that Procizumab has entered clinical evaluation and might be available to our patients as soon as in 2026/27."

Supported by

The project is funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Brandeburg Ministry for Labor, Social Affairs, Health, Women and Family (MASGF).

EFRE Logo go
Land Brandenburg Logo
Land Brandenburg Logo go
BSFZ Logo go